Morning Movers
Watch us on YouTube Live at 8:30AM EST

Travel Stocks – Remain on watch after yesterday’s announcement from the CDC saying people should avoid traveling on cruise ships regardless of their vaccination status, as daily COVID-19 cases in the country climb to record highs due to the fast-spreading Omicron variant. The move delivers another blow to the cruise industry that had just started returning to the seas in June after a months-long suspension of voyages caused by the pandemic. The CDC on Thursday raised its COVID-19 travel health notice level for cruise ships to its highest warning level, citing reports of COVID-19 outbreaks on cruises. CCL, RCL, NCLH, UAL, AAL, DAL, SAVE, LUV

NIO.NY -0.86%
Nio Inc – Active again premarket after yesterday’s rally, the stock ended the session up nearly 15% yesterday releasing weeks of selling pressure that has been weighing the stock down. The entire Chinese sector was sharply higher on the day.

AAPL.NQ -0.08%
Apple Inc – New data from the WSJ showed the company secured the top spot for phone sales in China for a second straight month in November, according to market research data, driven by the success of the iPhone 13 series.

LCID.NQ -0.62%
Lucid Group – Looking to add to yesterday’s 8% rally after Citigroup announced it was resuming coverage of the EV start-up with a buy rating and a $57 price target. To reach its target valuation, Citi says, Lucid “needs to successfully navigate production ramp-ups” and get itself at least enough revenue to attach a P/S ratio to the stock. Until Lucid succeeds at that, Citi says that it must “rate the stock High Risk.”

PTON.NQ -1.48%
Peloton Interactive – Lower again after JMP securities downgrades to market perform from market outperform.

AMD.NQ 0.71%
Advanced Micro Devices – Said it now expects to complete a $35 billion all-stock takeover deal for rival Xilinx during the first quarter of 2022, delayed from its prior 2021 year-end target.

MDRR.NQ 27.45%
Medalist Diversified Reit – Shares of Virginia-based real estate investment trust are sharply higher after announcing a share repurchase program of up to $2.4 mln, according to Reuters calculation.

XERS.NQ 22.63%
Xeris Biopharma – U.S. FDA on Thursday approved the company’s drug, Recorlev, for treating adult patients with a type of Cushing’s syndrome for whom surgery is not an option or has not been curative. The company expects to commercially launch recorlev in Q1 2022.

Leave a Reply

Your email address will not be published.